Search

Your search keyword '"Shelekhova T"' showing total 104 results

Search Constraints

Start Over You searched for: Author "Shelekhova T" Remove constraint Author: "Shelekhova T"
104 results on '"Shelekhova T"'

Search Results

10. Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study

12. PB2021: QUALITY OF LIFE AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD): RESULTS OF A REAL-WORLD EVIDENCE STUDY

13. P1724: QUALITY OF LIFE AND UNMET NEEDS AMONG PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASM PATIENTS: RESULTS OF THE NATIONWIDE SURVEY

14. PB2308: QUALITY OF LIFE AND CLINICAL OUTCOMES IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) DURING TREATMENT WITH ROMIPLOSTIM IN A REAL-WORLD SETTING

15. P1207: MULTICENTER RANDOMIZED CONTROLLED (COMPARATIVE) OPEN PROSPECTIVE STUDY TO EVALUATE THE EFFICACY OF THE R-DA-EPOCH-21 AND R-MNHL-BFM-90 ± AUTO- HSCT PROGRAMS IN PATIENTS WITH DE NOVO DIFFUSE B-CELL LAR

20. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

21. Efficacy and safety of weekly carfilzomib (70 mg/m(2)), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

22. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

23. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies

24. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

27. BRENTUXIMAB VEDOTIN FOR TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN A REAL WORLD SETTING: CLINICAL OUTCOMES AND IMPACT ON QUALITY OF LIFE

28. Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m(2) and Once-Weekly at 70 mg/m(2) in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

29. Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001.

30. New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants

31. EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001

33. 902P Quality of life and response to treatment with ixazomib-lenalidomide-dexamethasone (IRd) in patients with relapsed/refractory multiple myeloma (RRMM) in a real-world setting

34. Trip to Girvas

35. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma

37. INTERIM RESULTS OF EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS IN THE RUSSIAN FEDERATION: INTERMEDIATE RESULTS

39. PS1104 EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA AMONG THE ADULT POPULATION OF THE RUSSIAN FEDERATION

41. The results of the use of Octofactor in patients with moderate and severe hemophilia A (data from a prospective, multicenter, open-label, observational study)

44. Quality of working life of surgeons in multidisciplinary hospitals

45. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

46. EFFICACY OF PHYSICAL REHABILITATION IN THE FIRST YEAR AFTER KIDNEY TRANSPLANTATION.

47. Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML.

48. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty

49. Diatomites of Karelia for glass production.

50. Reconstruction of the relative level of the White Sea during the Lateglacial – Holocene according to lithological, diatom analyses and radiocarbon dating of small lakes bottom sediments in the area of the Chupa settlement (North Karelia, Russia)

Catalog

Books, media, physical & digital resources